We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Becton Sells 50.1% Stake in Respiratory Business to Apax
Read MoreHide Full Article
Leading global medical technology company, Becton, Dickinson and Co. (BDX - Free Report) or BD, announced the launch of a JV with Apax Partners, christened Vyaire Medical. The JV would be a standalone, global respiratory solutions company and will have an estimated annual revenue of over $800 million. Becton also sold a 50.1% stake in its Respiratory Solutions business to funds advised by Apax Partners, a private equity firm. The company plans to use net proceeds for share repurchases. BD will retain a 49.9% minority interest in the new company.
The new JV, Vyaire Medical includes all business lines within BD's Respiratory Solutions business. This consists of Ventilation, Respiratory Diagnostics, Vital Signs and AirLife. BD said its Respiratory Solutions facilities will be transferred to the new company, including locations in California, Minnesota, Mexico, Brazil, Germany and China. The new company will employ more than 5,000 associates around the world.
Based in Franklin Lakes, NJ, Becton, Dickinson, popularly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents.
An innovative product pipeline is the key growth driver at BD. A huge number of regulatory approvals both in the U.S. and international markets are facilitating expansion of the company’s product portfolio.
The company also has a partnership with Central Admixture Pharmacy Services (CAPS). Under this collaboratyion, BD Intelliport Medication Management System customers will be allowed to buy a portfolio of the frequently used CAPS pre-filled anesthesia syringes.
We believe that such partnerships and collaborations will lend BD a competitive edge and eventually boost its overall results. Although the Zacks Consensus Estimate for the full year remained unchanged at $8.56 over the last seven days, it reflects year-over-year growth of almost 19.6%.
Key Picks
A few notable stocks in the medical product sector are Quidel Corp. (QDEL - Free Report) , NuVasive, Inc. and GW Pharmaceuticals plc .
Quidel is expected to record earnings growth of 20%, higher than the industry average of 14.8% over the next five years. It has a four-quarter average earning surprise of 59.39%.
NuVasive has a trailing four-quarter average earning surprise of 18.98%. For the past five years, the stock saw a 16.6% earnings growth compared to the industry average of 5%.
GW Pharmaceuticals has a four-quarter average earning surprise of 41.67%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Becton Sells 50.1% Stake in Respiratory Business to Apax
Leading global medical technology company, Becton, Dickinson and Co. (BDX - Free Report) or BD, announced the launch of a JV with Apax Partners, christened Vyaire Medical. The JV would be a standalone, global respiratory solutions company and will have an estimated annual revenue of over $800 million. Becton also sold a 50.1% stake in its Respiratory Solutions business to funds advised by Apax Partners, a private equity firm. The company plans to use net proceeds for share repurchases. BD will retain a 49.9% minority interest in the new company.
The new JV, Vyaire Medical includes all business lines within BD's Respiratory Solutions business. This consists of Ventilation, Respiratory Diagnostics, Vital Signs and AirLife. BD said its Respiratory Solutions facilities will be transferred to the new company, including locations in California, Minnesota, Mexico, Brazil, Germany and China. The new company will employ more than 5,000 associates around the world.
Based in Franklin Lakes, NJ, Becton, Dickinson, popularly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents.
BECTON DICKINSO Price
BECTON DICKINSO Price | BECTON DICKINSO Quote
An innovative product pipeline is the key growth driver at BD. A huge number of regulatory approvals both in the U.S. and international markets are facilitating expansion of the company’s product portfolio.
The company also has a partnership with Central Admixture Pharmacy Services (CAPS). Under this collaboratyion, BD Intelliport Medication Management System customers will be allowed to buy a portfolio of the frequently used CAPS pre-filled anesthesia syringes.
We believe that such partnerships and collaborations will lend BD a competitive edge and eventually boost its overall results. Although the Zacks Consensus Estimate for the full year remained unchanged at $8.56 over the last seven days, it reflects year-over-year growth of almost 19.6%.
Key Picks
A few notable stocks in the medical product sector are Quidel Corp. (QDEL - Free Report) , NuVasive, Inc. and GW Pharmaceuticals plc .
Quidel is expected to record earnings growth of 20%, higher than the industry average of 14.8% over the next five years. It has a four-quarter average earning surprise of 59.39%.
NuVasive has a trailing four-quarter average earning surprise of 18.98%. For the past five years, the stock saw a 16.6% earnings growth compared to the industry average of 5%.
GW Pharmaceuticals has a four-quarter average earning surprise of 41.67%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>